Royce & Associates LP Grows Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Royce & Associates LP grew its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 13.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,119,385 shares of the medical instruments supplier's stock after acquiring an additional 133,312 shares during the quarter. Royce & Associates LP owned about 2.77% of AngioDynamics worth $10,254,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Rhumbline Advisers increased its position in AngioDynamics by 1.7% during the fourth quarter. Rhumbline Advisers now owns 60,479 shares of the medical instruments supplier's stock worth $554,000 after purchasing an additional 1,021 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of AngioDynamics by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 329,090 shares of the medical instruments supplier's stock worth $3,014,000 after buying an additional 2,270 shares during the last quarter. Quarry LP raised its position in shares of AngioDynamics by 40.9% in the 3rd quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier's stock worth $66,000 after buying an additional 2,471 shares during the period. SG Americas Securities LLC boosted its holdings in AngioDynamics by 21.3% in the fourth quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier's stock valued at $147,000 after acquiring an additional 2,832 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in AngioDynamics during the fourth quarter valued at about $28,000. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

AngioDynamics Stock Up 0.5 %

Shares of ANGO stock traded up $0.05 during mid-day trading on Friday, reaching $9.92. The company's stock had a trading volume of 636,948 shares, compared to its average volume of 564,170. The firm has a market capitalization of $401.42 million, a PE ratio of -1.76 and a beta of 0.56. The company's 50 day simple moving average is $10.70 and its 200-day simple moving average is $8.68. AngioDynamics, Inc. has a 12-month low of $5.26 and a 12-month high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company had revenue of $72.90 million for the quarter, compared to analysts' expectations of $70.93 million. During the same quarter in the previous year, the firm posted ($0.05) earnings per share. The firm's quarterly revenue was down .1% on a year-over-year basis. As a group, research analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Insider Buying and Selling at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the business's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. The trade was a 8.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 5.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Separately, HC Wainwright raised their price objective on AngioDynamics from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Friday, January 10th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.